Welcome to the latest update from Professional Affairs! This fall has been packed with major developments—from the release of Maximum Fair Prices for Medicare drugs to continued government focus of pharmacy benefit managers and much more.
Welcome to the first Professional Affairs blog! We plan on sharing a periodic post to recap some of the major news, journal articles, reports, and other publications from around the web that have come out since our last post. As this is our first blog, we’ll try to adequately cover the whirlwind that was July and early August 2024.
The FDA continues to approve novel therapies, but concerns arise due to the costs of certain treatments. To address this, the AMCP organized a forum to explore solutions. Stakeholders recognize the benefits of high-investment medications, but uptake of payment strategies has been slow. Gradual changes, education, and collaboration are essential to improve predictability, affordability, and accessibility for patients.
Proceedings from the AMCP Partnership Forum on High-Investment Medications.
Presentation from the AMCP Partnership Forum: High-Investment Medications.
